$-0.09 EPS Expected for Veru Inc. (VERU)

Analysts expect Veru Inc. (NASDAQ:VERU) to report $-0.09 EPS on January, 1.They anticipate $0.01 EPS change or 10.00 % from last quarter’s $-0.1 EPS. After having $-0.15 EPS previously, Veru Inc.’s analysts see -40.00 % EPS growth. The stock decreased 0.33% or $0.005 during the last trading session, reaching $1.51. About 149,010 shares traded or 37.12% up from the average. Veru Inc. (NASDAQ:VERU) has risen 21.48% since December 7, 2017 and is uptrending. It has outperformed by 5.86% the S&P500.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products. The company has market cap of $94.27 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It currently has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

More notable recent Veru Inc. (NASDAQ:VERU) news were published by: Globenewswire.com which released: “Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer – GlobeNewswire” on September 12, 2018, also Seekingalpha.com with their article: “Veru Healthcare: The Merger And What Lies Ahead – Seeking Alpha” published on June 13, 2017, Globenewswire.com published: “The Female Health Company / Veru Healthcare appoints new President of Global Public Health Sector Division – GlobeNewswire” on November 15, 2016. More interesting news about Veru Inc. (NASDAQ:VERU) were released by: Globenewswire.com and their article: “The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice President of Clinical Development – GlobeNewswire” published on April 11, 2017 as well as Finance.Yahoo.com‘s news article titled: “Here’s the memo Elon Musk just sent announcing a major shake-up at Tesla – Yahoo Finance” with publication date: May 14, 2018.

Veru Inc. (NASDAQ:VERU) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.